Tag: Kamada

  • Breakfast News: Sirius XM Holdings Inc. (NASDAQ:SIRI), Applied Materials, Inc. (NASDAQ:AMAT), Ericsson (NASDAQ:ERIC), Vodafone Group Plc (ADR) (NASDAQ:VOD), Kamada (NASDAQ:KMDA)

    TheStreet Ratings team reiterates its “hold” rating on Sirius XM Holdings Inc. (NASDAQ:SIRI) with a ratings score of C+. Sirius XM Holdings Inc. (NASDAQ:SIRI) stock opened today at $3.15 and is currently trading at $3.09. The stock showed a positive weekly performance of 0.00%.

    Applied Materials Inc. (NASDAQ:AMAT) reported second quarter adjusted EPS of $0.28 after the close Thursday, up from $0.16 last year. Analysts expected EPS of $0.28. The company expects third quarter adjusted EPS to be in the range of $0.25 to $0.29. Analysts currently expect EPS of $0.27. Applied Materials, Inc. (NASDAQ:AMAT) stock opened at $19.40, in current trading session and currently is at $20.15, by gaining 7.81%. The 52 week range of $14.32 – $21.16. Company’s market capitalization is 24.40 billion.

    Ericsson (ADR) (NASDAQ:ERIC) offers an integrated portfolio of CSP billing and policy solutions that fulfill the needs of all segments of billing. This award is presented to Ericsson for demonstrating excellence by capturing the highest market share within the global CSP billing rating and charging segment. Ericsson (ADR) (NASDAQ:ERIC) stock is currently trading at $12.36. The EPS of the stock is 0.61. Company’s market capitalization is 40.85 billion.

    Warren Buffett’s Berkshire Hathaway Inc. disclosed a holding in Verizon Group Plc (ADR) (NASDAQ:VOD)in a wager that the telecommunications company will benefit after buying out its partner in the largest U.S. wireless business. Vodafone Group Plc (ADR) (NASDAQ:VOD) stock opened the session at $36.47, and now is at $36.32. The 52 week range of the Vodafone Group Plc (ADR) (NASDAQ:VOD) stock remained $35.01 – $72.55 and the day range was $36.32 – $36.48.

    Kamada Ltd. (NASDAQ:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).Kamada Ltd (NASDAQ:KMDA) stock opened today at $9.61 and is currently trading at $9.23.